Corporate Strategy

• Continue the clinical development of intranasal administration of Foralumab (for neurodegenerative disease indication SPMS).
• Advance to a Phase 1b clinical development trial of orally-administered Foralumab for the treatment of Crohn’s disease.
• Submit an IND for Anti-IL-6R (TZLS-501) monoclonal antibodies.
• Explore the combination of milciclib and gemcitabine in NSCLC subjects with pan KRAS-positive mutations.
  
• Seek orphan drugs fast track or breakthrough designation for our product candidates where warranted.